title: Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?
authors.affiliation: Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX abdulghani@uthscsa.edu.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Abdul-Ghani
mesh_terms: D000218:Adamantane / Q000008:administration & dosage / Q000031:analogs & derivatives*; D001559:Benzhydryl Compounds / Q000008:administration & dosage*; D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004151:Dipeptides / Q000008:administration & dosage*; D005260:Female; D005960:Glucosides / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008687:Metformin / Q000008:administration & dosage*
chemical_list: D001559:Benzhydryl Compounds; D001786:Blood Glucose; D004151:Dipeptides; D005960:Glucosides; C529054:dapagliflozin; D008687:Metformin; C502994:saxagliptin; D000218:Adamantane